Cargando…

Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer

Purpose: Mediastinal and hilar lymph node metastasis is one of the recurrence patterns after definitive treatment of lung cancer. Salvage radiotherapy (RT) can be a treatment option for lymph node metastasis. However, the usefulness of additional RT remains unclear after surgery or RT for the primar...

Descripción completa

Detalles Bibliográficos
Autores principales: Shirai, Katsuyuki, Kubota, Yoshiki, Ohno, Tatsuya, Saitoh, Jun-ichi, Abe, Takanori, Mizukami, Tatsuji, Mori, Yasumasa, Kawamura, Hidemasa, Akahane, Keiko, Nakano, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692658/
https://www.ncbi.nlm.nih.gov/pubmed/31448233
http://dx.doi.org/10.3389/fonc.2019.00731
_version_ 1783443596126453760
author Shirai, Katsuyuki
Kubota, Yoshiki
Ohno, Tatsuya
Saitoh, Jun-ichi
Abe, Takanori
Mizukami, Tatsuji
Mori, Yasumasa
Kawamura, Hidemasa
Akahane, Keiko
Nakano, Takashi
author_facet Shirai, Katsuyuki
Kubota, Yoshiki
Ohno, Tatsuya
Saitoh, Jun-ichi
Abe, Takanori
Mizukami, Tatsuji
Mori, Yasumasa
Kawamura, Hidemasa
Akahane, Keiko
Nakano, Takashi
author_sort Shirai, Katsuyuki
collection PubMed
description Purpose: Mediastinal and hilar lymph node metastasis is one of the recurrence patterns after definitive treatment of lung cancer. Salvage radiotherapy (RT) can be a treatment option for lymph node metastasis. However, the usefulness of additional RT remains unclear after surgery or RT for the primary lung tumor. We retrospectively evaluated the efficacy and safety of hypofractionated carbon-ion RT for isolated lymph node metastasis. Methods and Materials: Between April 2013 and August 2016, 15 consecutive patients with isolated lymph node metastasis underwent carbon-ion RT. The pretreatment evaluations confirmed the isolated lymph node metastasis and the absence of local recurrence or distant metastasis, which was oligometastatic disease. The median age was 72 (range, 51–83) years, with 11 male patients. The first treatments for primary lung tumors were carbon-ion RT for 8 patients and surgery for 7 patients. There were 9 adenocarcinomas, 4 squamous cell carcinomas, 1 adenosquamous cell carcinoma, and 1 mucoepidermoid carcinoma. Most patients (93%) were irradiated with 52.8 Gy relative biological effectiveness in 12 fractions for 3 weeks. There were no patients treated with concurrent or adjuvant therapy such as chemotherapy, molecular-targeted therapy, or immunotherapy. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (version 4.0). Results: The median follow-up for surviving patients was 28 months. One patient experienced local lymph node recurrence, and the 2-year local control rate was 92% for all patients. Distant metastasis was observed in 7 patients, and 2-year progression-free survival rate was 47%. During follow-up, there were 4 deaths from lung cancer, and the 2-year overall survival rate was 75%. There were 2 patients with acute grade 2 esophagitis and 2 with late grade 2 cough, which were improved by conservative therapy. There were no other grade 2 or higher adverse events. Conclusions: Hypofractionated carbon-ion RT showed excellent local control and overall survival without severe toxicities in lung cancer patients with isolated lymph node metastasis after surgery or carbon-ion RT for primary lung tumors. A multi-institutional prospective study is required to establish the efficacy and safety of carbon-ion RT.
format Online
Article
Text
id pubmed-6692658
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66926582019-08-23 Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer Shirai, Katsuyuki Kubota, Yoshiki Ohno, Tatsuya Saitoh, Jun-ichi Abe, Takanori Mizukami, Tatsuji Mori, Yasumasa Kawamura, Hidemasa Akahane, Keiko Nakano, Takashi Front Oncol Oncology Purpose: Mediastinal and hilar lymph node metastasis is one of the recurrence patterns after definitive treatment of lung cancer. Salvage radiotherapy (RT) can be a treatment option for lymph node metastasis. However, the usefulness of additional RT remains unclear after surgery or RT for the primary lung tumor. We retrospectively evaluated the efficacy and safety of hypofractionated carbon-ion RT for isolated lymph node metastasis. Methods and Materials: Between April 2013 and August 2016, 15 consecutive patients with isolated lymph node metastasis underwent carbon-ion RT. The pretreatment evaluations confirmed the isolated lymph node metastasis and the absence of local recurrence or distant metastasis, which was oligometastatic disease. The median age was 72 (range, 51–83) years, with 11 male patients. The first treatments for primary lung tumors were carbon-ion RT for 8 patients and surgery for 7 patients. There were 9 adenocarcinomas, 4 squamous cell carcinomas, 1 adenosquamous cell carcinoma, and 1 mucoepidermoid carcinoma. Most patients (93%) were irradiated with 52.8 Gy relative biological effectiveness in 12 fractions for 3 weeks. There were no patients treated with concurrent or adjuvant therapy such as chemotherapy, molecular-targeted therapy, or immunotherapy. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (version 4.0). Results: The median follow-up for surviving patients was 28 months. One patient experienced local lymph node recurrence, and the 2-year local control rate was 92% for all patients. Distant metastasis was observed in 7 patients, and 2-year progression-free survival rate was 47%. During follow-up, there were 4 deaths from lung cancer, and the 2-year overall survival rate was 75%. There were 2 patients with acute grade 2 esophagitis and 2 with late grade 2 cough, which were improved by conservative therapy. There were no other grade 2 or higher adverse events. Conclusions: Hypofractionated carbon-ion RT showed excellent local control and overall survival without severe toxicities in lung cancer patients with isolated lymph node metastasis after surgery or carbon-ion RT for primary lung tumors. A multi-institutional prospective study is required to establish the efficacy and safety of carbon-ion RT. Frontiers Media S.A. 2019-08-07 /pmc/articles/PMC6692658/ /pubmed/31448233 http://dx.doi.org/10.3389/fonc.2019.00731 Text en Copyright © 2019 Shirai, Kubota, Ohno, Saitoh, Abe, Mizukami, Mori, Kawamura, Akahane and Nakano. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Shirai, Katsuyuki
Kubota, Yoshiki
Ohno, Tatsuya
Saitoh, Jun-ichi
Abe, Takanori
Mizukami, Tatsuji
Mori, Yasumasa
Kawamura, Hidemasa
Akahane, Keiko
Nakano, Takashi
Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer
title Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer
title_full Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer
title_fullStr Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer
title_full_unstemmed Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer
title_short Carbon-ion Radiotherapy for Isolated Lymph Node Metastasis After Surgery or Radiotherapy for Lung Cancer
title_sort carbon-ion radiotherapy for isolated lymph node metastasis after surgery or radiotherapy for lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692658/
https://www.ncbi.nlm.nih.gov/pubmed/31448233
http://dx.doi.org/10.3389/fonc.2019.00731
work_keys_str_mv AT shiraikatsuyuki carbonionradiotherapyforisolatedlymphnodemetastasisaftersurgeryorradiotherapyforlungcancer
AT kubotayoshiki carbonionradiotherapyforisolatedlymphnodemetastasisaftersurgeryorradiotherapyforlungcancer
AT ohnotatsuya carbonionradiotherapyforisolatedlymphnodemetastasisaftersurgeryorradiotherapyforlungcancer
AT saitohjunichi carbonionradiotherapyforisolatedlymphnodemetastasisaftersurgeryorradiotherapyforlungcancer
AT abetakanori carbonionradiotherapyforisolatedlymphnodemetastasisaftersurgeryorradiotherapyforlungcancer
AT mizukamitatsuji carbonionradiotherapyforisolatedlymphnodemetastasisaftersurgeryorradiotherapyforlungcancer
AT moriyasumasa carbonionradiotherapyforisolatedlymphnodemetastasisaftersurgeryorradiotherapyforlungcancer
AT kawamurahidemasa carbonionradiotherapyforisolatedlymphnodemetastasisaftersurgeryorradiotherapyforlungcancer
AT akahanekeiko carbonionradiotherapyforisolatedlymphnodemetastasisaftersurgeryorradiotherapyforlungcancer
AT nakanotakashi carbonionradiotherapyforisolatedlymphnodemetastasisaftersurgeryorradiotherapyforlungcancer